In TUXEDO-2, ticagrelor failed to meet the bar for noninferiority, with most outcomes hinting at an advantage for prasugrel.
NEW ORLEANS, LA—Ticagrelor did not prove to be noninferior to prasugrel as part of dual antiplatelet therapy…
Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD
